Pfizer-BioNTech COVID-19 vaccine overview and safety (also known as COMIRNATY)

Details

• Corporate Authors:
  National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.
• Description:
  Updated Oct. 16, 2021
  
  Pfizer-BioNTech (COMIRNATY) Name Change
  
  Pfizer-BioNTech (COMIRNATY) received U.S. Food and Drug Administration (FDA) approval on August 23, 2021, for individuals 16 years of age and older. Once vaccines are approved by the FDA, companies can market the vaccines under brand names. COMIRNATY is the brand name for the Pfizer-BioNTech COVID-19 Vaccine. Now that the FDA-authorized Pfizer-BioNTech COVID-19 vaccine has been approved by the FDA for individuals 16 years of age and older, it will be marketed as COMIRNATY. The use of the name Pfizer-BioNTech will still be used for individuals 12-15 years old since this age group has not been approved. There has been no change in the formulation of the vaccine since the name change.
  
  
• Subjects:
  Coronavirus Infections/prevention & Control COVID-19 Vaccines COVID-19/prevention & Control Immunization, Secondary Vaccines
• Document Type:
  Webpage
• Name as Subject:
  Pfizer-BioNTech COVID-19 vaccine ; COMIRNATY
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:17e41265b4a16d0841a3ccee4dbc400e7f3fd79f2e3405608dbf74b6fc8190ec
• Download URL:
  https://stacks.cdc.gov/view/cdc/110815/cdc_110815_DS1.pdf
• File Type:
  [PDF - 591.78 KB ]